摘要
目的探究奥洛他定联合普拉洛芬滴眼液治疗过敏性结膜炎的临床疗效及对泪膜稳定性的影响。方法选取2022年7月~2023年2月期间门诊诊治的过敏性结膜炎患者60例。按随机数字表法将60例患者分为试验组(30例)以及对照组(30例)。对照组给予奥洛他定滴眼液治疗,试验组在对照组的基础上给予普拉洛芬滴眼液治疗。比较两组的临床疗效、泪膜稳定性[泪膜破裂时间(BUT)和角膜荧光素染色试验(CFS)评分]、临床症状改善情况。结果试验组的治疗总有效率(28例/30例,93.33%)高于对照组(24例/30例,80.00%)(P<0.05)。治疗后与治疗前相比,两组BUT提升,CFS评分下降,且试验组的BUT高于对照组,CFS评分低于对照组(P<0.05)。治疗后两组的畏光、流泪、眼痒、异物感评分与治疗前相比下降,且试验组低于对照组(P<0.05)。结论过敏性结膜炎患者应用奥洛他定联合普拉洛芬滴眼液有利于维持其泪膜的稳定,改善患者眼部症状,且治疗后临床疗效提高。
Objective To explore the clinical efficacy of olopatadine combined with prauprofen eye drops in the treatment of allergic conjunctivitis and its effect on tear film stability.Methods 60 patients with allergic conjunctivitis diagnosed and treated in outpatient department from July 2022 to February 2023 were selected.Sixty patients were divided into the experimental group(30 cases)and the matched group(30 cases)using a random number table method.The matched group was treated with olopatadine eye drops,and the experimental group was treated with praprofen eye drops on the basis of the matched group.Compare the clinical efficacy,tear film stability[Tear film rupture time(BUT)and corneal fluorescence staining test(CFS)score],and improvement of clinical symptoms between the two groups.Results The total effective rate of treatment in the experimental group(28 cases/30 cases,93.33%)was higher than that in the matched group(24 cases/30 cases,80.00%)(P<0.05).After treatment,the two groups showed an increase in BUT and a decrease in CFS scores compared to before treatment.The BUT of the experimental group was higher than that of the matched group,and the CFS score was lower than that of the matched group(P<0.05).After treatment,the scores of photophobia,tearing,eye itching,and foreign body sensation in both groups decreased compared to before treatment,and the experimental group was lower than the matched group(P<0.05).Conclusion In patients with allergic conjunctivitis,the application of olopatadine combined with prauprofen eye drops is beneficial to maintain the stability of their tear film,improve the patients'eye symptoms,and improve the clinical efficacy after treatment.
作者
唐溢文
TANG Yi-wen(Department of Ophthalmology,Jiangsu Provincial Hospital of Traditional Chinese Medicine,Nanjing 210000,China)
出处
《中国处方药》
2023年第12期136-139,共4页
Journal of China Prescription Drug